Home

Estimé incident éperon ardelyx press release Prestataire Affiches Sophie

Ardelyx (@ardelyx) / X
Ardelyx (@ardelyx) / X

AFTER HOUR TRADING IS HALTED : r/ARDELYX
AFTER HOUR TRADING IS HALTED : r/ARDELYX

Hyperphosphatemia Pipeline Insight Report 2023 (Updated)
Hyperphosphatemia Pipeline Insight Report 2023 (Updated)

Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases |  FinancialContent Business Page
Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases | FinancialContent Business Page

Ardelyx Prepares for Battle with FDA Over Rejected CKD Drug | BioSpace
Ardelyx Prepares for Battle with FDA Over Rejected CKD Drug | BioSpace

Ardelyx wins FDA approval for phosphate absorption inhibitor -  Pharmaceutical Technology
Ardelyx wins FDA approval for phosphate absorption inhibitor - Pharmaceutical Technology

ARDX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of  September 28, 2021 in the Class Action Filed on Behalf of Ardelyx, Inc.  Limited Shareholders
ARDX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 28, 2021 in the Class Action Filed on Behalf of Ardelyx, Inc. Limited Shareholders

Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis
Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis

Ardelyx, Inc. on LinkedIn: Press Release: Ardelyx Announces Poster  Presentations on XPHOZAH®…
Ardelyx, Inc. on LinkedIn: Press Release: Ardelyx Announces Poster Presentations on XPHOZAH®…

🦍💎 $ARDX ✋🚀
🦍💎 $ARDX ✋🚀

And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%. |  Internet | Biotech Stock Review
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%. | Internet | Biotech Stock Review

Ardelyx
Ardelyx

Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis
Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis

Ardelyx: Q3 Earnings Snapshot -October 31, 2023 at 07:30 am EDT |  MarketScreener
Ardelyx: Q3 Earnings Snapshot -October 31, 2023 at 07:30 am EDT | MarketScreener

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ardelyx, Inc.  (ARDX) Investigation
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ardelyx, Inc. (ARDX) Investigation

Ardelyx to Raise $110 Million in a Private Placement
Ardelyx to Raise $110 Million in a Private Placement

Ardelyx Grants Stock Options & RSUs to New Employees
Ardelyx Grants Stock Options & RSUs to New Employees

Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases |  FinancialContent Business Page
Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases | FinancialContent Business Page

Ardelyx Announces Proposed Public Offering of Common Stock
Ardelyx Announces Proposed Public Offering of Common Stock

News & Events | Ardelyx, Inc.
News & Events | Ardelyx, Inc.

Ardelyx, Inc. (NASDAQ: ARDX) Long Term Investor Notice: Lawsuit
Ardelyx, Inc. (NASDAQ: ARDX) Long Term Investor Notice: Lawsuit

Adding Ardelyx (ARDX) $1.57 to Watch List. | Internet | Biotech Stock Review
Adding Ardelyx (ARDX) $1.57 to Watch List. | Internet | Biotech Stock Review

Ardelyx Inc.(NASDAQ: ARDX)-Can it Continue to Outdo Estimates?
Ardelyx Inc.(NASDAQ: ARDX)-Can it Continue to Outdo Estimates?

Scripts : r/ARDELYX
Scripts : r/ARDELYX

Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the  Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease  on Dialysis
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial | PDF |  Chronic Kidney Disease | Therapy
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial | PDF | Chronic Kidney Disease | Therapy